Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation

Transplantation

Volumn 93, Issue 7, 2012, Pages 723-728

  Bosch, Wendelyn ^a   Heckman, Michael G ^a   Pungpapong, Surakit ^a   Diehl, Nancy N ^a   Shalev, Jefree A ^a   Hellinger, Walter C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytomegalovirus; Death; Graft loss; Hepatitis C virus; Liver transplantation

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GRAFT FAILURE; HEPATIC ALLOGRAFT INFLAMMATION; HEPATITIS C; HUMAN; INFLAMMATION; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT VIRUS INFECTION; RETROSPECTIVE STUDY;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLORIDA; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859269072     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182472876     Document Type: Article

References (26)

1. Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl Int 2009; 22: 1031
2. Razonable RR. Cytomegalovirus infection after liver transplantation: Current concepts and challenges. World J Gastroenterol 2008; 14: 4849
3. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870
4. Hodson EM, Craig JC, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; (2): CD003774
5. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390
6. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645
7. Bosch W, Heckman MG, Diehl NN, et al. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11: 2181
8. Porter SB, Reddy KR. Factors that influence the severity of recurrent hepatitis C virus following liver transplantation. Clin Liver Dis 2003; 7: 603
9. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14(suppl 2): S36
10. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721
11. Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35: 974
12. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362
13. Chopra KB, Demetris AJ, Blakolmer K, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76: 1487
14. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461
15. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830
16. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70: 1454
17. Nebbia G, Mattes FM, Cholongitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13: 130
18. Humar A, Washburn K, Freeman R, et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007; 13: 1422
19. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228
20. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761
21. Cytomegalovirus. Am J Transplant 2004; 4(suppl 10): 51
22. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094
23. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305
24. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31: 792
25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289
26. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710.